Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychotic Disorders | 5 | 2022 | 135 | 2.010 |
Why?
|
| Schizophrenia | 6 | 2021 | 300 | 1.540 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3154 | 1.080 |
Why?
|
| Genes, Recessive | 1 | 2025 | 185 | 0.900 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2025 | 501 | 0.770 |
Why?
|
| Genome-Wide Association Study | 3 | 2025 | 1684 | 0.710 |
Why?
|
| Schizotypal Personality Disorder | 1 | 2019 | 7 | 0.640 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 238 | 0.620 |
Why?
|
| Schizophrenic Psychology | 2 | 2014 | 82 | 0.540 |
Why?
|
| Suicide, Attempted | 2 | 2014 | 128 | 0.510 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 215 | 0.370 |
Why?
|
| Inpatients | 1 | 2014 | 496 | 0.340 |
Why?
|
| Cognition Disorders | 1 | 2014 | 553 | 0.340 |
Why?
|
| Cognition | 1 | 2014 | 722 | 0.320 |
Why?
|
| Autism Spectrum Disorder | 2 | 2025 | 384 | 0.290 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2024 | 31 | 0.220 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2023 | 777 | 0.220 |
Why?
|
| Loss of Function Mutation | 2 | 2021 | 149 | 0.220 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 184 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 332 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 42 | 0.200 |
Why?
|
| Case-Control Studies | 4 | 2025 | 3284 | 0.200 |
Why?
|
| Machine Learning | 1 | 2025 | 250 | 0.190 |
Why?
|
| Temporal Lobe | 1 | 2022 | 111 | 0.190 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 84 | 0.190 |
Why?
|
| Humans | 18 | 2025 | 124728 | 0.170 |
Why?
|
| Mutation, Missense | 2 | 2021 | 875 | 0.170 |
Why?
|
| Mental Disorders | 2 | 2024 | 820 | 0.160 |
Why?
|
| Risk | 1 | 2021 | 755 | 0.160 |
Why?
|
| Neural Stem Cells | 1 | 2020 | 118 | 0.160 |
Why?
|
| Alleles | 1 | 2024 | 1613 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 949 | 0.160 |
Why?
|
| Interview, Psychological | 1 | 2019 | 96 | 0.150 |
Why?
|
| Antipsychotic Agents | 2 | 2020 | 361 | 0.150 |
Why?
|
| Neurotransmitter Agents | 1 | 2018 | 146 | 0.140 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 712 | 0.130 |
Why?
|
| Research Personnel | 1 | 2017 | 118 | 0.130 |
Why?
|
| Syndrome | 1 | 2019 | 1119 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2025 | 1548 | 0.130 |
Why?
|
| Genomics | 1 | 2023 | 1501 | 0.120 |
Why?
|
| Risk Factors | 3 | 2025 | 10286 | 0.120 |
Why?
|
| Phenotype | 1 | 2024 | 4255 | 0.110 |
Why?
|
| Heroin | 1 | 2014 | 19 | 0.110 |
Why?
|
| Transcriptome | 1 | 2020 | 952 | 0.110 |
Why?
|
| Middle Aged | 5 | 2025 | 26797 | 0.110 |
Why?
|
| Heroin Dependence | 1 | 2014 | 56 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2895 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 115 | 0.110 |
Why?
|
| Male | 7 | 2025 | 61270 | 0.110 |
Why?
|
| Attention | 1 | 2014 | 200 | 0.100 |
Why?
|
| Language | 1 | 2014 | 201 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1270 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2520 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3432 | 0.090 |
Why?
|
| Adult | 5 | 2024 | 29489 | 0.090 |
Why?
|
| Female | 6 | 2024 | 66570 | 0.090 |
Why?
|
| Memory | 1 | 2014 | 361 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 924 | 0.090 |
Why?
|
| Neurons | 1 | 2020 | 1926 | 0.090 |
Why?
|
| Brain | 1 | 2022 | 2982 | 0.090 |
Why?
|
| Mutation | 1 | 2023 | 5825 | 0.080 |
Why?
|
| Receptors, Eph Family | 1 | 2008 | 20 | 0.080 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2008 | 88 | 0.070 |
Why?
|
| Aged | 2 | 2024 | 19764 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 120 | 0.070 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2025 | 36 | 0.060 |
Why?
|
| Young Adult | 1 | 2019 | 9024 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2025 | 45 | 0.060 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2025 | 96 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2024 | 20 | 0.060 |
Why?
|
| Pharmacogenomic Testing | 1 | 2024 | 37 | 0.060 |
Why?
|
| Latin America | 1 | 2023 | 92 | 0.050 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2022 | 32 | 0.050 |
Why?
|
| Haplotypes | 1 | 2024 | 522 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2008 | 714 | 0.050 |
Why?
|
| Epirizole | 1 | 2020 | 2 | 0.050 |
Why?
|
| Trimipramine | 1 | 2020 | 2 | 0.050 |
Why?
|
| Perphenazine | 1 | 2020 | 6 | 0.050 |
Why?
|
| Trazodone | 1 | 2020 | 5 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 19287 | 0.040 |
Why?
|
| Carbamazepine | 1 | 2020 | 48 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 139 | 0.040 |
Why?
|
| Naloxone | 1 | 2020 | 48 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 101 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1532 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 222 | 0.040 |
Why?
|
| Risperidone | 1 | 2020 | 59 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 281 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 109 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2020 | 171 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 883 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 192 | 0.040 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2018 | 21 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 307 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 286 | 0.040 |
Why?
|
| Genotype | 1 | 2024 | 2556 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 275 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2020 | 375 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2020 | 646 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1701 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1090 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2014 | 141 | 0.030 |
Why?
|
| China | 1 | 2013 | 243 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 240 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 4806 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6147 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 590 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2245 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2013 | 222 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 806 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 1189 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2008 | 168 | 0.020 |
Why?
|
| Protein Folding | 1 | 2008 | 216 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 314 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 217 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 532 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2008 | 223 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 2447 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 148 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 759 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 34025 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 17577 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 3716 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2746 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2008 | 770 | 0.010 |
Why?
|